A new paradigm has emerged of patients with chronic cough that does not respond to asthma, rhinitis, and/or GERD therapy. Allergists need to understand the different therapeutic agents available now and in the future and their mechanisms of action in all stages of cough.
This podcast series is supported by an educational grant from Merck & Co., Inc.
PIDD Disparities Miniseries
Patients with Primary Immunodeficiency Diseases (PIDD) are not only susceptible to infection, but they are also at risk for other, non-infectious, complications. Some of these non-infectious complications can be life-threatening for the patient. This session is intended to discuss how to monitor for these complications, the pathophysiology behind these complications, and the impact new immune therapies have on management of patients with PIDD.